Dark Blue Therapeutics
Biopharmaceutical company focused on discovery and preclinical development of precision oncology small molecules. The organization combines academic partnerships, functional genomics, structural biology, medicinal chemistry and translational medicine to identify cancer dependencies and develop targeted inhibitors, molecular glues and targeted protein degraders for biomarker-defined patient populations.
Industries
Nr. of Employees
small (1-50)
Dark Blue Therapeutics
Hayakawa Building, Edmund Halley Road, The Oxford Science Park, Oxford, OX4 4GB, United Kingdom
Products
MLLT1/3 targeted protein degrader program
Discovery and preclinical development of oral small-molecule degraders targeting histone reader proteins MLLT1 and MLLT3 to disrupt the Super Elongation Complex for treatment of acute leukemias and solid tumors.
ADAR1 inhibitor and degrader program
Discovery of small-molecule inhibitors and targeted degraders of the RNA-editing enzyme ADAR1, supported by structural biology, protein production and cellular assays to exploit tumor dependencies and modulate anti-tumor immunity.
SMO (Smoothened) small-molecule inhibitor program
Discovery of novel small molecules binding an alternative pocket of the GPCR Smoothened (SMO) to achieve a differentiated mechanism of action with potential improved safety and activity profiles versus first-generation SMO drugs.
MLLT1/3 targeted protein degrader program
Discovery and preclinical development of oral small-molecule degraders targeting histone reader proteins MLLT1 and MLLT3 to disrupt the Super Elongation Complex for treatment of acute leukemias and solid tumors.
ADAR1 inhibitor and degrader program
Discovery of small-molecule inhibitors and targeted degraders of the RNA-editing enzyme ADAR1, supported by structural biology, protein production and cellular assays to exploit tumor dependencies and modulate anti-tumor immunity.
SMO (Smoothened) small-molecule inhibitor program
Discovery of novel small molecules binding an alternative pocket of the GPCR Smoothened (SMO) to achieve a differentiated mechanism of action with potential improved safety and activity profiles versus first-generation SMO drugs.
Services
Partnerships with academic groups to source target insights, sponsor research and embed academic expertise into project teams.
End-to-end discovery platform spanning target validation, screening, structural biology, medicinal chemistry, translational studies and IND-enabling preclinical work.
Partnerships with academic groups to source target insights, sponsor research and embed academic expertise into project teams.
End-to-end discovery platform spanning target validation, screening, structural biology, medicinal chemistry, translational studies and IND-enabling preclinical work.
Expertise Areas
- Target discovery and validation
- Functional genomics
- Structural biology and crystallography
- Medicinal chemistry and lead optimization
Key Technologies
- X-ray crystallography
- Structural biology
- Functional genomics screens
- Protein expression and purification
News & Updates
Announcement of industry executive Edwin Moses joining as Chairman to support progression of lead programs toward clinical trials and strategic growth.
Announcement of industry executive Edwin Moses joining as Chairman to support progression of lead programs toward clinical trials and strategic growth.